Literature DB >> 22449349

Recent advances and prognosis in idiopathic membranous nephropathy.

Paul E Segal1, Michael J Choi.   

Abstract

Idiopathic membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome. Recently, progress has been made in understanding the pathogenesis of idiopathic MN with the finding of M-type phospholipase A2 receptor (PLA2R) antibodies in the serum and immune complexes of glomeruli in the majority of adult idiopathic MN patients. In the future, the detection of M-type PLA2R antibodies may help distinguish patients with primary MN who require aggressive immunosuppressive therapy from those with secondary disease. Levels of circulating antibody to this receptor may help in monitoring disease activity and in gauging response to therapy, as changes in antibody levels may precede changes in proteinuria. The degree of renal dysfunction or change in renal function over time and the level of persistent proteinuria are key prognostic factors in the decision to initiate therapy in idiopathic MN patients. Although spontaneous remissions occur in ~30% of patients, partial and complete remissions help to define the clinical course of an individual patient.
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449349     DOI: 10.1053/j.ackd.2012.01.007

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  13 in total

1.  Serum uric acid is an independent predictor of renal outcomes in patients with idiopathic membranous nephropathy.

Authors:  Ji Zhang; Min Pan; JianNa Zhang; XiaoHan You; Dou Li; Fan Lin; GuoYuan Lu
Journal:  Int Urol Nephrol       Date:  2019-08-28       Impact factor: 2.370

Review 2.  Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis.

Authors:  Shou-Liang Hu; Dan Wang; Wen-Jun Gou; Qing-Feng Lei; Te-An Ma; Jun-Zhang Cheng
Journal:  J Nephrol       Date:  2014-02-06       Impact factor: 3.902

3.  Role of the glucocorticoid receptor in the recurrence of primary nephrotic syndrome.

Authors:  Yumei Liang; Yinyin Chen; Ying Chen; Yuting Gong
Journal:  Exp Ther Med       Date:  2015-07-30       Impact factor: 2.447

Review 4.  Glomerular diseases: membranous nephropathy--a modern view.

Authors:  Claudio Ponticelli; Richard J Glassock
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 8.237

5.  Membranous nephropathy: Treatment outline and risk stratification.

Authors:  Ziad Arabi
Journal:  Avicenna J Med       Date:  2012-07

6.  Phosphotriesterase-related protein sensed albuminuria and conferred renal tubular cell activation in membranous nephropathy.

Authors:  Chao-Wen Cheng; Li-Chien Chang; Tzu-Ling Tseng; Chia-Chao Wu; Yuh-Feng Lin; Jin-Shuen Chen
Journal:  J Biomed Sci       Date:  2014-04-22       Impact factor: 8.410

7.  Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy.

Authors:  W Cui; X Lu; X Min; M Liu; S Guan; Y Wang; M Luo; W Li; Q Li; W Dong; L Miao; P Luo
Journal:  Braz J Med Biol Res       Date:  2017-03-23       Impact factor: 2.590

8.  Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.

Authors:  Mario Menschikowski; Albert Hagelgans; Brit Nacke; Carsten Jandeck; Olga Sukocheva; Gabriele Siegert
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

9.  Retrospective Study of Phospholipase A2 Receptor and IgG Subclasses in Glomerular Deposits in Chinese Patients with Membranous Nephropathy.

Authors:  Hong-Rui Dong; Yan-Yan Wang; Xiao-Hong Cheng; Guo-Qing Wang; Li-Jun Sun; Hong Cheng; Yi-Pu Chen
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

10.  Clinicopathological features of idiopathic membranous nephropathy combined with IgA nephropathy: a retrospective analysis of 9 cases.

Authors:  Ruimin Hu; Guolan Xing; Huijuan Wu; Zhigang Zhang
Journal:  Diagn Pathol       Date:  2016-09-13       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.